Daily FNArena News - Australia

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

A miss on the Q4 gross margin and Eli Lilly targeting the CPAP market have kept ResMed shares under selling pressure since Friday last week

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

Independent Investment Research updates developments among Australia’s listed investment companies and provides comparative data

Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

The ASX200 gained 2.9% in July led by energy and banking stocks and performed broadly in line with overseas indices

Tim Boreham takes a look at the fortunes of Australia’s listed insurers and insurance brokers

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments